Bright Minds Biosciences Inc (DRUG)

$28.37 +0.36 (1.29%)
Market Cap 199.84M
Revenue (ttm) 0.00
Net Income (ttm) -2.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 18,900
Avg Vol 40,438
Day's Range N/A - N/A
Shares Out 7.04M
Stochastic %K 90%
Beta -6.01
Analysts Strong Sell
Price Target $83.25

Company Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indicatio...

Industry: Biotechnology
Sector: Healthcare
Phone: 647 865 8622
Address:
19 Vestry Street, New York, United States
cupcakes4jesus
cupcakes4jesus Jul. 7 at 2:38 AM
$DRUG this is going back to $15
0 · Reply
Camelinvesting
Camelinvesting Jul. 6 at 9:35 AM
$DRUG will buy if cross 29.82$
0 · Reply
Doozio
Doozio Jul. 4 at 3:40 PM
$ACOG chop chop huckleberries the XBI names are about to join da 🎉 during 🐒🍌🧠⏰♾️. They even went false break down on da $DRUG zzzzzz
1 · Reply
gstock568
gstock568 Jul. 3 at 2:18 PM
$WINT It’d be aMaZiNg if WINT was the next $RGC $DRUG or $BMNR 💪
0 · Reply
One2look
One2look Jul. 3 at 2:13 PM
$LIXT the new $DRUG?
0 · Reply
Trader1141
Trader1141 Jul. 2 at 11:14 PM
$BON had a new order for 16 Millions and didnt run? $MOGO $CYN $DRUG
0 · Reply
BiotechValues
BiotechValues Jul. 2 at 9:45 PM
$JSPR looks like market starting to wake up to the huge valuation gap between JSPR and $CLDX. CLDX at $1.4B market cap and JSPR only $100M. If JSPR can demonstrate a better efficacy/safety profile than CLDX with this month's CSU key data, expect that gap to narrow considerably. Obv there are some nuances - CLDX having more cash, ahead in timeline, etc, but this is a similar setup to what happened with $DRUG and $LBPH. Assuming no dilution, a $1.4B market cap would be $93 for JSPR, 100% dilution would be $46. Things can get crazy with 15M O/S
2 · Reply
RealSituation
RealSituation Jul. 2 at 3:12 PM
$HSDT When I remember $DRUG I get more patience to hold this one 🔥🔥🔥
0 · Reply
JarvisFlow
JarvisFlow Jul. 2 at 1:00 PM
Cantor Fitzgerald updates rating for Bright Minds Biosciences ( $DRUG ) to Overweight.
0 · Reply
mhswizard
mhswizard Jun. 30 at 10:35 PM
$BMNR reminds me of $DRUG back in October 🥲
0 · Reply
Latest News on DRUG
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

May 20, 2025, 8:00 AM EDT - 6 weeks ago

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

May 7, 2025, 4:45 PM EDT - 2 months ago

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Apr 28, 2025, 8:00 AM EDT - 2 months ago

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Apr 16, 2025, 12:09 PM EDT - 2 months ago

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

Jan 26, 2025, 6:32 AM EST - 5 months ago

Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Jan 7, 2025, 6:50 AM EST - 6 months ago

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Nov 4, 2024, 2:41 PM EST - 8 months ago

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

Oct 30, 2024, 1:07 AM EDT - 8 months ago

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Oct 28, 2024, 8:21 AM EDT - 8 months ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

NVCT

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Oct 21, 2024, 8:30 AM EDT - 9 months ago

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Oct 18, 2024, 6:50 AM EDT - 9 months ago

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Oct 16, 2024, 10:45 AM EDT - 9 months ago

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Bright Minds is Unaware of Any Material Changes

Oct 15, 2024, 9:09 PM EDT - 9 months ago

Bright Minds is Unaware of Any Material Changes

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Oct 3, 2024, 9:00 AM EDT - 9 months ago

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Sep 19, 2024, 10:00 AM EDT - 10 months ago

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Sep 12, 2024, 8:00 AM EDT - 10 months ago

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Aug 8, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 20, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Jul 12, 2023, 10:33 AM EDT - 2 years ago

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Bright Minds Announces Effective Date of Share Consolidation

Jul 11, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Effective Date of Share Consolidation

Bright Minds Announces Proposed Share Consolidation

Jun 22, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Proposed Share Consolidation

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Apr 19, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Apr 10, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Feb 27, 2023, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Bright Minds Biosciences Announces Non-Executive Director Appointment

Feb 17, 2023, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Announces Non-Executive Director Appointment

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Feb 8, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Jan 27, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Bright Minds Biosciences Announces Resignation of Board Member

Jan 9, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Resignation of Board Member

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Dec 2, 2022, 7:07 PM EST - 2 years ago

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Announces Non-Brokered Private Placement

Nov 28, 2022, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Announces Non-Brokered Private Placement

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Nov 23, 2022, 11:35 AM EST - 2 years ago

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Sep 7, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Aug 31, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Aug 30, 2022, 3:35 PM EDT - 3 years ago

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

Aug 23, 2022, 9:07 PM EDT - 3 years ago

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

Bright Minds Announces Overnight Marketed Offering of Units

Aug 22, 2022, 7:05 PM EDT - 3 years ago

Bright Minds Announces Overnight Marketed Offering of Units

Bright Minds Biosciences Comments on Recent Trading Activity

Aug 18, 2022, 3:34 PM EDT - 3 years ago

Bright Minds Biosciences Comments on Recent Trading Activity

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

Jun 27, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

May 12, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

May 2, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Nov 30, 2021, 7:30 AM EST - 3 years ago

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Nov 4, 2021, 8:52 AM EDT - 3 years ago

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Nov 3, 2021, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

cupcakes4jesus
cupcakes4jesus Jul. 7 at 2:38 AM
$DRUG this is going back to $15
0 · Reply
Camelinvesting
Camelinvesting Jul. 6 at 9:35 AM
$DRUG will buy if cross 29.82$
0 · Reply
Doozio
Doozio Jul. 4 at 3:40 PM
$ACOG chop chop huckleberries the XBI names are about to join da 🎉 during 🐒🍌🧠⏰♾️. They even went false break down on da $DRUG zzzzzz
1 · Reply
gstock568
gstock568 Jul. 3 at 2:18 PM
$WINT It’d be aMaZiNg if WINT was the next $RGC $DRUG or $BMNR 💪
0 · Reply
One2look
One2look Jul. 3 at 2:13 PM
$LIXT the new $DRUG?
0 · Reply
Trader1141
Trader1141 Jul. 2 at 11:14 PM
$BON had a new order for 16 Millions and didnt run? $MOGO $CYN $DRUG
0 · Reply
BiotechValues
BiotechValues Jul. 2 at 9:45 PM
$JSPR looks like market starting to wake up to the huge valuation gap between JSPR and $CLDX. CLDX at $1.4B market cap and JSPR only $100M. If JSPR can demonstrate a better efficacy/safety profile than CLDX with this month's CSU key data, expect that gap to narrow considerably. Obv there are some nuances - CLDX having more cash, ahead in timeline, etc, but this is a similar setup to what happened with $DRUG and $LBPH. Assuming no dilution, a $1.4B market cap would be $93 for JSPR, 100% dilution would be $46. Things can get crazy with 15M O/S
2 · Reply
RealSituation
RealSituation Jul. 2 at 3:12 PM
$HSDT When I remember $DRUG I get more patience to hold this one 🔥🔥🔥
0 · Reply
JarvisFlow
JarvisFlow Jul. 2 at 1:00 PM
Cantor Fitzgerald updates rating for Bright Minds Biosciences ( $DRUG ) to Overweight.
0 · Reply
mhswizard
mhswizard Jun. 30 at 10:35 PM
$BMNR reminds me of $DRUG back in October 🥲
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 30 at 8:15 PM
$ALT $DRUG $NUVB $TNXP a very nice day for Biotech 🚀
2 · Reply
RealSituation
RealSituation Jun. 30 at 5:09 PM
$HSDT Who knows may be after RS this time it may run like $DRUG did after I sold a month later it did this to me will take the pain here and hold $1TO $50+
1 · Reply
DingoJones
DingoJones Jun. 30 at 4:06 PM
$DRUG when is data expected? I cant find info anywhere
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 30 at 3:32 PM
$DRUG loaded. PT 26.5
0 · Reply
havepatiencee
havepatiencee Jun. 30 at 3:30 PM
$GNS anyone remember what happened with $DRUG
2 · Reply
Ron_Burn
Ron_Burn Jun. 30 at 1:58 PM
$DRUG 👀
0 · Reply
midbagholder
midbagholder Jun. 28 at 12:22 AM
$DRUG $GDHG $MLGO $NUKK $SBET stop bring this China shit in this room thanks
2 · Reply
ProfessorDman1
ProfessorDman1 Jun. 27 at 11:43 PM
$GDHG every dips being bought here : 1.6M exchange so far most came in AH .. what do you think will happen Monday and next week ? Ummm 🤔 $MLGO $NUKK $SBET $DRUG n many other set ups acted same heavy accumulations days prior to 1000%-2000%+ runner.. GDHG can go 5X-10x with right news and volume in multi day sessions ..
1 · Reply
dbr_island
dbr_island Jun. 27 at 7:32 PM
$LFWD sometimes when you are 5 steps ahead of the market It looks like your late But that is what adding the dips are for Eventually my plays blossom Some just happen right away like $AMIX Some take a couple days like $VOR Some take a week or so like $CTOR Some take a month or so like $DRUG But eventually they ALL pay out 💰💰💰
0 · Reply
Luckyjs38
Luckyjs38 Jun. 27 at 6:44 PM
$ENVB I believe we see a massive break out into natural price discovery. extremely undervalued in my opinion we could see a run like $RGC $HKD $ROOT $DRUG 👀🚀 lets see
0 · Reply
MaskMaker
MaskMaker Jun. 27 at 6:23 PM
$PIII The best being accumulated quietly imo $NUTX $GRRR $DRUG
1 · Reply
nomendivitiae
nomendivitiae Jun. 27 at 5:32 PM
$CTOR Fuck it' s a cancer drug providing munch needed relief to suffering people. There's tons of good karma on this. So let's give it a $DRUG like run. It’s a deserving ticker. If you as I do, have fuck you money. Then let's do something good with it going into the weekend with a great feeling LFG!!!
1 · Reply